Most of the studies regarding cyclosporin 'A' production through fungi concentrate around Tolypocladium inflatum. This is mainly due to lower reported production of this drug in other fungi. The present study was therefore conducted to explore indigenous isolates of Aspergillus terreus for synthesis of this drug and defining a production medium for obtaining high yield of cyclosporin 'A'. For this purpose carbon and nitrogen sources were optimized for the selected best strain of A. terreus. Overall results depicted that the best cyclosporin 'A' yield from selected Aspergillus terreus (FCBP58) could be obtained by using production medium containing glucose 10% as carbon source and peptone 0.5% as nitrogen source. This modification in production medium enhanced drug synthesis by selected fungi significantly. The production capabilities when compared with biomass of fungi there was found no relationship between the two confirming that the medium modification increased overall drug synthesis powers of the fungi.
INTRODUCTION
Secondary metabolites of filamentous fungi are of extreme interest to humankind due to their pharmaceutical and/or toxic properties (6) . Cyclosporin 'A' is a main product of secondary metabolism of fungal species originally identified as strains of Trichoderma polysporum (12) but currently classified as belonging to the species Tolypocladium inflatum. Other soil inhabiting filamentous fungi like Fusarium solani (26) Neocosmospora vasinfecta (24) and Fusarium oxysporum (13) have also been reported to produce lower levels of cyclosporins. Recently, different strains of A. terreus have been identified as new producers of cyclosporine 'A' (27, 28) .
Cyclosporin 'A' is a nonpolar cyclic peptide of eleven amino acids with a molecular weight of 1202.6. It exhibits a narrow spectrum of antifungal activity and in addition has immunosuppressant properties (12) . This is a strong and selective immunosuppressant in transplant surgery inhibiting the rejection of allogeneic grafts and is also a very promising drug against autoimmune and parasitic diseases (8) . In addition this is applied in reversing multidrug resistance in several types of cancers (11) . The drug is produced by submerged culturing of aerobic filamentous fungi (17) . Workers have also isolated the enzyme fraction from T. inflatum extracts (5, 18) . Fermentation conditions (21) and nutrient medium have already been optimized for the production of cyclosporin 'A' by T. inflatum.
Some workers obtained best production of the drug from T.
inflatum by exploiting sorbose in their fermentation media (2, 15) while others found glucose and yeast extract to be best carbon and nitrogen sources (16) . Investigation by Sallam et al. Cyclosporin 'A' production was significantly influenced by the addition of amino acids (16, 19) . The external addition of L-leucine and L-valine during exponential growth phase highly increased the production of cyclosporin 'A' (1, 3). The productivity from T. inflatum was markedly increased by utilizing immobilized fungus (20, 22) in the presence of Lvaline (9, 10). Sallam et al. (27) investigated the formation of cyclosporin 'A' by immobilizing the spores and mycelium of A. terreus and found L-valine to increase the production. The current study is conducted to detect high yielding strains of A.
terreus among several local isolates and enhance the production powers of local isolate by altering carbon and nitrogen sources in nutritional medium.
MATERIALS AND METHODS

Procurement of fungal strains
Nine strains of A. terreus were obtained from the First Fungal Culture Bank of Pakistan (FCBP). The strains were preserved on Malt Extract Agar (MEA) at 4 ºC and were provided in the form of slants in culture tubes. The strains were revived on MEA plates (malt extract 2 %, agar 2 %, pH 6.5) and the inoculated plates were incubated at 27±1 ºC for 4-5 days. The strain numbers and their origins of isolation are mentioned in Table 1 . 
Extraction of cyclosporin 'A'
The extraction of cyclosporin 'A' was performed by using n-butyl in equal quantity in the medium and flasks were incubated at 200 rpm and 30±2 ºC for 24 hours. Two distinguish immiscible layers of top organic phase and bottom aqueous phase were formed containing extraction solution and medium respectively. The organic phase was carefully separated by using separating funnel and evaporated under Media modification for cyclosporine 'A' production vacuum till dryness at 40 ºC. The dried sample was weighed and dissolved in 30 mL methanol.
Biomass harvest
The biomass was harvested by filtering aqueous layer of cultivation medium containing fungal pellets using Whatman filter paper No.1. The biomass was dried in oven overnight at 40 ºC and was weighed. A 5mL of prepared seed inoculum was inoculated in the prepared cultivate media of different sets and incubated on orbital shaker at 200 rpm and 30±2 ºC for 10 days. The extraction, analysis and estimation of cyclosporin 'A' was performed by the same procedure as described above for the selection of best yielding strain.
RESULTS AND DISCUSSION
Screening of fungal strains
Present study was conducted to design a production media most conducive for cyclosporin 'A' production using A. terreus strain. In the first step nine isolates of the selected fungal species were checked for the drug production. terreus. The project was therefore planned to enhance the production potential of FCBP58 for increased drug production. (left) and harvested mixture from Aspergillus terreus FCBP58 (right). Table 2 . Cyclosporin 'A' production by nine different Aspergillus terreus strains.
Confirmation of cyclosporin 'A'
Cyclosporin-related metabolites are reported to have a broad spectrum of antifungal activity and a narrow spectrum of activity against bacterial cultures (25) . The harvested mixture assumed to have cyclosporins showed strong antifungal activity against A. niger when tested through well method. The inhibition zone of restricted growth of A. niger was 1.15 cm (Fig. 2) .
When run through HPLC, a peak appeared between 2.7 and 2.8 min (Fig. 5) , which was confirmed as cyclosporin 'A' when compared with Sandimmun Neoral ® capsules containing 100 mg cyclosporin 'A' as active ingredient and pure cyclosporine 'A' as authentic drug supplied by Fluka analytical, Japan. Sandimmun Neoral ® capsules showed a clear peak at 2.768 min (Fig. 3 ) whereas authentic compound recorded at 2.81 min (Fig. 4) . 
Effect of carbon source
Six different carbon sources were tried in this study to augment the drug production (Table 3) . Highest tested concentration was 10 % at which when glucose was added, it proved to be the most effective carbon source significantly increasing cyclosporin 'A' production up to 358.5 µg/mL ( Beside glucose, cellulose also proved a fairly good carbon source in case of A. terreus, when used in concentration of 2 %, it increased cyclosporin 'A' production from 62.4 µg/mL to 235 µg/mL (Table 3) . Increase in concentration to 5 % result in 143.6 % increase in cyclosporin 'A' production. However it was lower in comparison to the treatment in which cellulose 2 % was used. Although cellulose is a complex carbohydrate (polysaccharide), but A. terreus is known to produce extracellular endo-β-1, 4-glucanase, exo-β-1, 4-glucanase with high levels of β-glucosidase and has the ability to utilize cellulose as carbon source. Previous studies also show increase in fungal biomass with increase of carbon sources (29) .
Effect of nitrogen sources
Peptone, trypton and casamino acids was used individually and then in combinations to check the productivity of cyclosporin 'A' (Table 4) . These three compounds are amino acid mixtures. Peptone when checked at lower concentration of 0.5 %, increased drug production spectacularly by 765.4 % (Fig 5C) . Peptones are derived from animal milk or meat digested by proteolytic digestion and contains small peptides along with fats, metals, salts, vitamins and many other biological compounds. As peptone can provide vitamins and metals along with amino acids it proved best supplement for drug enhancement in comparison to others. However, in agreement with these workers, an increase in total cyclosporine production was seen, but of considerably higher magnitude. L-valine may have a role of inducer to increase the transcription of genes for cyclosporin 'A' synthetase or other structural genes contributing to cyclosporin 'A' synthesis in our fungal strain, given the positive effect of the amino acid when added early in the fermentation. Some amino acids may act as inducers which must be added in exponential growth phase to manifest their ability to enhance secondary metabolite production.
C D Media modification for cyclosporine 'A' production
It is also possible that these amino acids may direct cell development in a manner favouring secondary metabolite production by affecting transcription of secondary metabolite genes during vegetative cell growth (14) .
The results showed that the modification of production medium by increasing glucose concentration to 10 % as carbon source and addition of lower peptone concentration of 0.5 % as nitrogen source along with valine (0.1 %) supplementation can significantly increase cyclosporin 'A' production.
Drug production versus fungal biomass
When increase in fungal biomass produced by selected strain in various modified media was compared to the increment of cyclosporin 'A' the drug production was not found directly associated with increase in biomass ( Fig. 6-8 
Drug production versus extract colour
The colour of the final extract containing cyclosporins showed variation from light yellow to dark reddish orange.
However, the darkness of colour also did not seem to correspond with any increment in amount of cyclosporin 'A'. In case of glucose, increase in sugar concentration in production medium increased drug production and also the colour intensity. It is supposed that the final extract is a combination of various cyclosporins and may posses some other compounds. The quantity of these compounds also varies with variation in the treatments.
This can affect the colour of final extract that do not directly relates to the increase in cyclosporin 'A' production. 
